MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
14.90
-0.10 (-0.67%)
At close: Dec 5, 2025, 4:00 PM EST
15.00
+0.10 (0.67%)
After-hours: Dec 5, 2025, 7:59 PM EST
MLTX Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for MLTX stock ranges from a low of $5.00 to a high of $85. The average analyst price target of $36.33 forecasts a 143.83% increase in the stock price over the next year.
Price Target: $36.33 (+143.83%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MLTX stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 3 | 4 |
| Buy | 5 | 5 | 4 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 8 | 8 | 7 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $26 | Strong Buy | Maintains | $30 → $26 | +74.50% | Nov 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $30 | Hold → Strong Buy | Upgrades | $30 | +101.34% | Nov 3, 2025 |
| Citigroup | Citigroup | Hold → Strong Sell Downgrades $5 | Hold → Strong Sell | Downgrades | $5 | -66.44% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 2, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $80 → $20 | Strong Buy | Maintains | $80 → $20 | +34.23% | Sep 30, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.63
from -1.89
EPS Next Year
-3.63
from -3.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.49 | -2.66 | ||||
| Avg | -3.63 | -3.63 | ||||
| Low | -3.62 | -4.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.